Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT06824883
Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
A Single-arm, Phase 2 Study of Sintilimab, Pegaspargase Combined with Gemcitabine and Oxaliplatin (P-P-GEMOX) Regimen for Newly Diagnosed Extranodal NK/T-Cell Lymphoma
Sponsor: Peking Union Medical College Hospital
Conditions
Extranodal NK/T-cell Lymphoma
Interventions
Immunochemotherapy
Updated 1 time since 2025 Last updated: Feb 8, 2025 Started: May 20, 2024 Primary completion: May 20, 2026 Completion: May 20, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Extranodal NK/T-cell Lymphoma and is currently actively recruiting participants. Peking Union Medical College Hospital leads this study, which shows 1 recorded version since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Peking Union Medical College Hospital
Data source: Peking Union Medical College Hospital
For direct contact, visit the study record on ClinicalTrials.gov .